| Completed | 2b | 75 | RoW | Sutezolid, PNU-100480, Bedaquiline, Delamanid, Moxifloxacin, BDM, Midazolam oral solution | Michael Hoelscher, European and Developing Countries Clinical Trials Partnership (EDCTP), Sequella, Inc., Radboud University Medical Center, University of California, San Francisco, German Federal Ministry of Education and Research | Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | 09/22 | 09/22 | | |
NCT05971602: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis |
|
|
| Recruiting | 2 | 514 | RoW | Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE), Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS), Isoniazid and Rifampicin (HR) | Bill & Melinda Gates Medical Research Institute, Global Alliance for TB Drug Development, Janssen Pharmaceutica, Otsuka Pharmaceutical Co., Ltd. | Pulmonary Tuberculosis | 10/27 | 10/27 | | |